Open AccessShort Term Analysis of New Single-Piece Aspheric Diffractive Trifocal Intraocular Lens Implantation
Author(s) -
К.B. Pershin,
N.F. Pashinova,
M.M. Konovalova,
А. Ю. Цыганков,
M.E. Konovalov,
Н. Э. Темиров
Publication year - 2019
Publication title -
oftalʹmologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.133
H-Index - 5
eISSN - 2500-0845
pISSN - 1816-5095
DOI - 10.18008/1816-5095-2019-1-19-25
Subject(s) - medicine , intraocular lens , ophthalmology , capsulorhexis , multifocal intraocular lens , cataract extraction , intraocular lenses , presbyopia , cataract surgery , surgery , prospective cohort study , phacoemulsification , visual acuity
Purpose . Evaluation of short-term (up to 9 months) results of new one-piece aspherical diffractive trifocal intraocular lens implantation. Patients and Methods . A prospective, open-label study included 65 patients (100 eyes) with presbyopia, who received cataract extraction with the implantation of a new IOL AcrySof PanOptix® trifocal. The average age of the patients was 60.0 ± 12.1 years. 35 patients underwent bilateral correction with multifocal IOLs, and 30 had a monolateral correction. In 21 % (n = 21) cases, femtolaser support of cataract extraction was performed. In 9 eyes (9 %) the primary posterior capsulorhexis was performed. The range of optical power of implanted IOLs was 13 to 30 D. The follow-up period was from 6 to 9 (6.8 ± 0.9) months. Results . On the 1 day after the MIOL implantation, an UCIVA increase was from 0.22 ± 0.19 to 0.76 ± 0.23 (p < 0.05), at follow-up to 6 months up to 0.85 ± 0.22. One day after surgery, the UCIVA increased from 0.23 ± 0.19 to 0.7 ± 0.25 (p < 0.05), with following raise up to 0.84 ± 0.24 in the maximum follow-up period of 6 months. UCFVA in the preoperative period was 0.27 ± 0.23, with an increase to 0.78 ± 0.23 (p < 0.05) for 1 day and 0.93 ± 0.18 at 6 months. The BCNVA increase was from 0.56 ± 0.25 before surgery to 0.8 ± 0.19 on the 1st day after cataract removal (p < 0.05) and 0.98 ± 0.16 at the 6 months follow-up period. Similar data (0.58 ± 0.29, 0.82 ± 0.21, and 0.95 ± 0.14) was noted for BCIVA. An BCFVA increase was from 0.71 ± 0.28 in the preoperative period to 1.0 ± 0.04 (p < 0.05) after 6 months. The primary endpoint of the study (BCFVA = 1.0) in the group was achieved in 83 % of cases (n = 83). The effect of glare was noted in 17 patients (26.1 %), halo in 9 (13.8 %), driving difficulties in 6 (9.2 %). The overwhelming majority of patients (96.9 %) rated the result of the operation as “excellent” (n = 51, 78.5 %) and “good” (n = 14, 21.5 %). Conclusion . Implantation of the examined IOL is associated with a high efficiency for near, intermediate distance and far vision correction. A new trifocal IOL may be recommended for use in clinical practice. Further comparative studies including other multifocal IOLs are needed to determine the indications and contraindications for its implantation.